Vazkepa

RSS

icosapent ethyl

Authorised
This medicine is authorised for use in the European Union.

Overview

Vazkepa is a medicine for reducing the risk of cardiovascular events such as heart attack, stroke and other problems caused by blocked blood circulation. It is for use as add-on treatment in adults being treated with a statin medicine who have high levels of triglycerides (a type of fat) in their blood.

Vazkepa is to be used in patients either with a cardiovascular disease (a condition that affects the heart or circulation) or with diabetes and another condition that increases the risk of cardiovascular events.

Vazkepa contains the active substance icosapent ethyl.

This EPAR was last updated on 14/04/2021

Authorisation details

Product details
Name
Vazkepa
Agency product number
EMEA/H/C/005398
Active substance
Icosapent ethyl
International non-proprietary name (INN) or common name
icosapent ethyl
Therapeutic area (MeSH)
Dyslipidemias
Anatomical therapeutic chemical (ATC) code
C10AX
Publication details
Marketing-authorisation holder
Amarin Pharmaceuticals Ireland Limited
Date of issue of marketing authorisation valid throughout the European Union
26/03/2021
Contact address

88 Harcourt Street
Dublin 2
D02DK18
Ireland

Product information

26/03/2021 Vazkepa - EMEA/H/C/005398 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Lipid modifying agents

Therapeutic indication

Indicated to reduce cardiovascular risk as an adjunct to statin therapy.

Assessment history

How useful was this page?

Add your rating
Average
2 ratings